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Abstract
Background: Golgi protein-73 (GP73) is a Golgi transmembrane glycoprotein elevated in numerous liver diseases.
Clinically, GP73 is strongly elevated in the serum of HCC patients and is thus regarded as a novel potential biomarker
for HCC. However, the mechanism leading to GP73 dysregulation in liver diseases remains unknown.
Results: This study determined that epithelium-specific ETS (ESE)-1, an epithelium-specific transcription factor, and
GP73 expressions were induced by IL-1β stimulation in vitro, and both were triggered during liver inflammation in vivo.
In hepatocellular carcinoma cells, the overexpression of ESE-1 induced GP73 expression, whereas its knock-down did
the opposite. Mechanistically, ESE-1 activated GP73 expression by directly binding to its promoter.
Conclusions: Our findings supported a novel paradigm for ESE-1 as a transcriptional mediator of GP73. This study
provided a possible mechanism for GP73 upregulation in liver diseases.
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Background
Golgi protein-73 (GP73), also known as GOLPH2 or
GOLM1, is a type II Golgi transmembrane glycoprotein
[1] and is predominantly expressed in epithelial cells [2].
It is upregulated in numerous liver diseases, including virus-
induced hepatitis (e.g., hepatitis B and C virus), alcohol-
induced liver disease, autoimmune hepatitis [3,4], liver
cirrhosis [4], and hepatocellular carcinoma cells (HCC)
[5-7]. Clinically, GP73 is strongly elevated in the serum
of HCC patients [8] and is thus regarded as a novel po-
tential biomarker for HCC [5-7].
Previous studies showed that GP73 is induced under
inflammatory conditions [3,9-11]. In HepG2 and Hep3B
cells, GP73 expression is elevated after treatment with
proinflammatory cytokine IL-6 [9]. Increased GP73 ex-
pression in SK-Hep-1 cells is associated with interferon
gamma (IFN-γ) stimulation [3]. In vivo, GP73 is upregu-
lated in a mouse model of CCl4-induced cirrhosis [10].
However, the mechanism by which these extracellular
signals trigger GP73 expression remains unclear.
ESE-1, also known as ELF-3, is a member of ESE subfam-
ily of ETS transcription factors. It is exclusively expressed in
epithelial cells and mainly contains two putative DNA bind-
ing domains, namely, the ETS and A/T hook domains [12].
Its ETS domain commonly binds a core consensus sequence
of GGAA [13]. Similar to GP73, ESE-1 is also induced by
proinflammatory factors such as IL-1ʲ, tumor necrosis
factor-ʱ [14], and lipopolysaccharide (LPS) [15,16]. More-
over, proinflammatory cytokine IL-1ʲ induces ESE-1 expres-
sion in chondrocytes [17] and prostate cancer cells [18].
In this study, we demonstrated that similar to ESE-1,
GP73 expression was also induced upon IL-1ʲ stimulation,
and was upregulated by ESE-1 in HCC cells. Mechanistic-
ally, we identified that ESE-1 activated GP73 expression by
directly binding to its promoter. Thus, ESE-1 was a novel
transcriptional regulator of GP73 in liver diseases.
Results
IL-1β stimulated both ESE-1 and GP73 expressions
Previous studies reported that under inflammatory con-
ditions, GP73 expression is elevated in hepatocytes [3,9].
Since ESE-1, an epithelial specific transcription factor, is
also induced by proinflammatory cytokine IL-1ʲ [17,18],
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http://www.cellandbioscience.com/content/4/1/76we asked whether ESE-1 played a role in the regulation
of GP73 expression. By first comparing the basal levels
of ESE-1 and GP73 proteins in different HCC cell lines
(HepG2, Hep3B, Huh7), we found that Huh7 cells with
high level of ESE-1 protein exhibited high level of GP73,
whereas HepG2 cells with minimal ESE-1 protein
showed minimal GP73 (Figure 1A). Similar correlation
of ESE-1 and GP73 expression was also observed in
other human and mouse hepatocytes (Additional file 1:
Figure S1). To determine whether the expression of
GP73 is also stimulated by IL-1ʲ, Hep3B and Huh7 cells
were subsequently treated with different doses of IL-1ʲ.
Both qPCR and Western blot analyses indicated that com-
pared with the untreated control in Hep3B (Figure 1B)
and Huh7 (Figure 1C) cells, ESE-1 was increased after
IL-1ʲ treatment, and that GP73 was also increased in a
dose-dependent manner. These results indicated that
ESE-1 and GP73 were induced in response to IL-1ʲ stimuli.
To determine ESE-1 and GP73 expressions under proin-
flammatory conditions in vivo, a mouse liver inflammation
model was used. Mice were intraperitoneally injected with
LPS and D-galactosamine [19]. Mice sera were collected
at different time points, and the levels of alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
were measured. The levels of ALTand AST, as the criteria
for inflammation response, peaked at 6 h post injection,
suggesting that liver inflammation was induced. Inflam-
mation was recovered after 72 h, as indicated by the de-
creased ALT and AST elevation (Figure 2A). The liver
tissues of the mice were collected at different time points,
and the mRNA levels of ESE-1 and GP73 were analyzed
using qPCR. ESE-1 expression peaked at 12 h, whereas
GP73 expression peaked at 24 h. Both expressions finally
recovered to normal level within 72 h (Figure 2B). The re-
sults of immunohistochemical analysis verified that GP73
expression was induced by liver inflammation (Figure 2C).
Next, we determined ESE-1 and GP73 expressions in
human HCC tissue samples using immunofluorescence
with serial sections of samples. HE staining was used to
present the pathological changes in liver tissues. Consist-
ent with the previous reports, GP73 was located in the
Golgi body [20], whereas ESE-1 was distributed in the
cytoplasm [21,22]. The regions with higher expression
level of ESE-1 also showed higher GP73 expression,
whereas in the para-carcinoma tissue, both proteins dis-
played lower expressions. The isotype-matched control
samples exhibited no staining (Figure 3).
These studies collectively identified that ESE-1 and
GP73 expressions were induced in response to IL-1ʲ
stimuli in vitro and were triggered during liver inflam-
mation in vivo. Both expressions were elevated in HCC
patient samples.
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Figure 1 ESE-1 and GP73 expressions were induced by IL-1β stimulation in vitro. (A) The basal levels of ESE-1 and GP73 expressions in
HepG2, Hep3B, and Huh7 cells were analyzed by conducting Western blot. (B) Hep3B cells were stimulated with different doses of IL-1β (2.5, 10,
and 20 ng/mL) for 48 h. IL-1β-induced ESE-1 and GP73 mRNA and protein levels were analyzed by performing qPCR and Western blot. (C) Huh7
cells were stimulated with different doses of IL-1β (10 and 20 ng/mL) for 48 h. ESE-1 and GP73 mRNA and protein levels were analyzed with qPCR
and Western blot. The values were normalized to GAPDH. Western blot was reprobed for GAPDH as a loading reference control.
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As previously indicated, ESE-1 and GP73 expressions
were induced by IL-1ʲ stimulation in vitro. We won-
dered whether ESE-1 regulated GP73 expression. An
ESE-1 expression plasmid was constructed, and its ex-
pression was confirmed by transfecting pCR3.1-ESE-1
plasmid into 293T cells (Figure 4A). When ESE-1 was
overexpressed in Hep3B cells, the transcript and protein
levels of GP73 increased accordingly (Figure 4B). Similar
results were also confirmed in Huh7 cells (Figure 4C).
To further confirm that ESE-1 is responsible for the
elevated GP73 expression, a mutant form of ESE-1 [12]
(lacking ETS domain, which was required for ESE-1
binding) (ʔESE-1) was constructed (Figure 4D). Compared
with ESE-1, the upregulatory effect on GP73 of ʔESE-1
was impaired in Hep3B and Huh7 cells (Figure 4E). These
findings signified that ESE-1 overexpression increased
GP73 expression.
By preparing an efficient retroviral shRNA vectors for
ESE-1, we also assessed whether ESE-1 upregulated
GP73 expression in the presence of IL-1ʲ. The transcript
and protein levels of GP73 decreased with ESE-1 knock-
down in Hep3B (Figure 4F) and Huh7 cells (Figure 4G)
with or without IL-1ʲ. GP73 protein level recovered after
ESE-1 expression in both knock-down cells (Figure 4H
and I). These results indicated that ESE-1 upregulated
GP73 expression.
ESE-1 bound to and activated GP73 promoter
To illustrate details of how ESE-1 regulated GP73 ex-
pression, ESE-1 (or ʔESE-1) and GP73 promoter re-
porter vectors were co-transfected into hepatocytes,
Huh7 and Hep3B. We found that ESE-1 but not ʔESE-1
efficiently activated GP73 promoter (Figure 5A and B).
Moreover, ESE-1 activated GP73 promoter in a dose-
dependent manner (Figure 5C). These results indicated
that ESE-1 activated GP73 promoter.
Based on the ESE-1 binding core sequences, the
possible ESE-1 binding sites were predicted in regions
I( −1110/–864), III (−734/–421), and IV (−421/–79) of
GP73 promoter (Figure 5D, upper panel). To confirm
that ESE-1 directly interacted with GP73 promoter,
the specific binding of ESE-1 to these DNA sequences
was analyzed with ChIP assay, followed by qPCR.
Compared with the IL-1ʲ untreated control, ESE-1
loading onto the corresponding promoters was signifi-
cantly enhanced after IL-1ʲ stimulation (Figure 5D,
lower panel), indicating that ESE-1 bound to the three
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Figure 2 ESE-1 and GP73 expressions were triggered during liver inflammation in vivo. The mouse liver inflammation model was constructed
by intraperitoneally injecting LPS (35 ng/kg) and D-galactosamine (250 mg/kg). (A) The levels of ALT and AST in mice sera were measured by full
automatic blood analyzer at different time points during liver inflammation. (B) The mRNA levels of mouse ESE-1 and GP73 in liver tissues were
measured with qPCR. (C) Mouse GP73 expression levels in liver tissues were analyzed at 0 and 24 h by accomplishing immunohistochemistry. Black
arrows depicted the location of GP73 protein.
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ing activity was strongly enhanced by IL-1ʲ treatment.
To further confirm that ESE-1 could bind to the three
regions of GP73 promoter, the corresponding deletion
mutants were constructed in these regions by deleting
the two adjacent possible ESE-1 binding sites. ʔ–989/–
965 and ʔ–918/–869 deletion mutants were located in
region I; ʔ–617/–583 was located in region III; and ʔ–
Figure 3 ESE-1 and GP73 were elevated in the liver tissues of patients with HCC. Liver tissues of HCC patients (n = 5) were collected and
fixed by formaldehyde. Hematoxylin–eosin (HE) staining was used to present the pathological changes in liver tissues. ESE-1 (red fluorescence)
and GP73 (green fluorescence) expression levels were analyzed by conducting immunofluorescence. Nuclei (blue fluorescence) were counterstained
with DAPI. The isotype-matched IgG was used as a negative control.
Wang et al. Cell & Bioscience 2014, 4:76 Page 4 of 10
http://www.cellandbioscience.com/content/4/1/76351/–365 and ʔ–261/–232 were located in region IV.
ESE-1 and GP73 full-length promoter (or deletion mutant
promoters) were co-transfected into Hep3B cells. The
results of luciferase reporter assays demonstrated that the
activities of ʔ–918/–869 and ʔ–617/–583 mutant pro-
moters were impaired compared with that of the GP73
full-length promoter, whereas the activity of ʔ–351/–365
was enhanced (Figure 5E). Therefore, ESE-1 could bind to
regions I and III with activating effect and region IV with
repressive activity. These results demonstrated that ESE-1
bound to GP73 promoter in multiple binding sites, which
was consistent with the results of the ChIP–qPCR assay.
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Figure 4 ESE-1 upregulated GP73 expression in HCC cells. (A) pCR3.1-ESE-1 plasmid was transfected into HEK293T cells and ESE-1 expression
was tested by Western blot 36 h after transfection. (B) pCR3.1-ESE-1 plasmid was transfected into Hep3B cells for 36 h, and GP73 mRNA and protein
levels were analyzed with qPCR and Western blot, respectively. (C) GP73 mRNA and protein levels were analyzed by adopting qPCR and Western blot
in Huh7 cells transfected with pCR3.1-ESE-1 plasmid. (D) pCR3.1-ΔESE-1 plasmid with deletion ETS domain of ESE-1 was constructed and transfected
into HEK293T cells. ΔESE-1 expression was confirmed by Western blot. (E) The empty vector (Mock) or ESE-1 or ΔESE-1 was transfected into Hep3B
and Huh7 cells, and GP73 expression was tested by Western blot. (F) ESE-1 was downregulated in Hep3B and (G) Huh7 cells by infecting them with
virus carrying the shRNA expression cassette against ESE-1 (shESE-1) or a non-target control (shGFP) with or without IL-1β stimulation. After 96 h,
the mRNA and protein levels of ESE-1 and GP73 were analyzed with qPCR and Western blot, respectively. (H) Hep3B and (I) Huh7 cells infected with
shESE-1 virus particles were transfected with pCR3.1-ESE-1 plasmid at 48 h post-infection. At 48 h after transfection, cells were harvested, and ESE-1
and GP73 proteins were analyzed with Western blot.
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http://www.cellandbioscience.com/content/4/1/76Figure 5 ESE-1 bound to and activated GP73 promoter. (A) The empty vector (Mock) or ESE-1 or ΔESE-1 and GP73 promoter were co-transfected into
Hep3B cells. The activity of GP73 promoter was measured by performing luciferase reporter assays after 36 h. (B) Similar to Hep3B cells, the activity of GP73
promoter was analyzed in Huh7 cells as (A). (C) Different doses of pCR3.1-ESE-1 plasmid and GP73 promoter were co-transfected into Hep3B cells. The activity
of GP73 promoter was analyzed by completing luciferase reporter assays 36 h after transfection. (D) The sketch map of GP73 promoter is shown above. The
possible ESE-1 binding sites were located in regions I (−1110/–864), III (−734/–421), and IV (−421/–79) of GP73 promoter. The results of ChIP–qPCR for
ESE-1 in Hep3B cells are shown below. (E) The pCR3.1-ESE-1 plasmid and GP73 full-length promoter or deletion ESE-1 binding sites mutants were
co-transfected into Hep3B cells. The activity of the promoters was analyzed by accomplishing luciferase reporter assays 36 h after transfection.
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regulated GP73 expression in HCC cells by directly
binding to and activating its promoter.
Discussion
GP73 is elevated in many liver diseases and is considered a
potential biomarker for HCC. However, little information
is known about the mechanism leading to elevated GP73
expression in liver diseases. Therefore, understanding the
mechanism of GP73 upregulation is of importance to de-
velop better diagnostic and therapeutic methods. The aim
of this study is to investigate the underlying mechanism of
GP73 upregulation in liver diseases.
GP73 expression is up-regulated in various hepatitis
and HCC, with the highest in serum of HCC patients
[7]. Many studies reported that HCC can be promoted
and exacerbated by inflammation [23-26]. Chronic in-
flammation is associated with persistent hepatic injury
and regeneration, leading to sequential development of
fibrosis, cirrhosis, and eventually HCC. Recently, several
inflammation-related signaling pathways, such as the nu-
clear factor-kappa B and signal transducer and activator
of transcription pathways, have been identified as key
players in these processes. To reveal the regulation
mechanism of GP73 expression in liver diseases, we ana-
lyzed GP73 expression in HCC cells under inflammation
conditions. We found that GP73 expression was upregu-
lated upon IL-1ʲ stimulation in vitro (Figure 1) and was
triggered during liver inflammation in vivo (Figure 2).
These findings conformed to previous stipulation that
GP73 is upregulated under inflammatory conditions.
The regulation mechanism of GP73 expression was fur-
ther realized by seeking for the key transcription factors.
We discovered that ESE-1 could significantly activate
GP73 promoter (Figure 5A). Based on the fact that both
ESE-1 and GP73 are expressed in epithelial cells [2,12],
and both are induced in response to IL-1ʲ stimuli, our
findings suggest that ESE-1 is at least one of the regula-
tory links between the inflammatory stimuli and the en-
hanced GP73 expression.
Since the ETS domain of ESE-1 is responsible for
DNA binding, it is reasonable that the upregulatory ef-
fect on GP73 of ʔESE-1 was impaired when compared
with ESE-1 in Hep3B and Huh7 cells (Figure 4E). How-
ever, recent studies showed that the ETS domain of
ESE-1 also mediated the protein-protein interactions
[27], and ESE-1 also contains a Pointed domain [12], an
A/T hook domain [12], and a serine- and aspartic acid-
rich domain [21]. Therefore, it is not surprising to find
that ʔESE-1 overexpression in Hep3B and Huh7 cells
showed minor discrepancy in inducing GP73 expression
compared with mock (Figure 4E), which is probably related
to different partners interacted with ESE-1 through differ-
ent domains in different cell context [27]. Multiple ETS
sites, including regions I (−1110/–864), III (−734/–421),
and IV (−421/–79), were predicted on GP73 promoter
based on the ESE-1 binding core sequence. The results
of the ChIP–qPCR assay (Figure 5D) and deletion ESE-
1 binding site mutants (Figure 5E) confirmed that mul-
tiple ESE-1 binding sites were available in GP73 promoter.
Similar results of a regulatory region with several ETS
binding sites are observed in other ESE-1 regulated genes,
such as SPRR2A, Endo A [12], TGF-ʲII receptor [28],
COX2 [15], and COL2A1 [17]. The observation of im-
paired activities by ʔ–918/–869 and ʔ–617/–583 mu-
tants and the enhanced activity by ʔ–351/–365 mutant
(Figure 5E) suggested that ESE-1 could interact with ei-
ther co-activators or co-repressors and may result in differ-
ent responses. This postulation was supported by the fact
that ESE-1 represses target gene expression by interacting
with Ku70 and Ku86 proteins, but yields such expression
by interacting with p300 and CREB-binding proteins [27].
In HCC, GP73 is upregulated in liver tissue and serum
[5-7]. However, the role of ESE-1 in HCC has never
been reported. This is the first report of the correlation
between ESE-1 and HCC. Previous studies suggested
that the intercellular location of ESE-1 is determined by
nuclear localization and nuclear export signals [21,22].
We found that ESE-1 located in cytoplasm and nuclear
in Hep3B and Huh7 cells, regardless of IL-1ʲ stimula-
tion (Additional file 2: Figure S2). Nevertheless, ESE-1
was mainly distributed in the cytoplasm in liver tissue of
HCC patients, which is consistent with the location of
ESE-1 in human breast cancer [21,22]. Additionally,
ESE-1 and GP73 expressions were identified to be ele-
vated and exhibited similar distribution in the liver tis-
sue of HCC patients (Figure 3). Importantly, ESE-1 is
upregulated in human cancers and prompts cancer de-
velopment [18,29,30]. These findings were important in
understanding the role of GP73 in HCC development
and progression.
The results of this study indicated that ESE-1 was an
important new contributing factor in controlling GP73
transcription in HCC cells. However, the delay in GP73
mRNA induction compared with ESE-1 after IL-1ʲ
stimulation in vitro (Additional file 3: Figure S3A and
S3B) and during liver inflammation in vivo (Figure 2B)
indicated that other factors activated after ESE-1 worked
in conjunction with ESE-1 to drive GP73 transcription
in response to inflammatory stimuli. A similar finding
was observed when the effects of ESE-1 on matrix me-
talloproteinase13 transcriptional control were investi-
gated in articular chondrocytes under proinflammatory
stress [31].
Conclusions
This study identified that ESE-1 and GP73 expressions
were induced by IL-1ʲ stimulation, and ESE-1
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binding to and activating its promoter. This study pro-
vided a possible mechanism for GP73 upregulation in
liver diseases. More detailed investigations on the mo-
lecular mechanisms of GP73 expression is expected to
contribute to understanding its functional implications
in diseases and evaluating its role as a novel cancer
marker.
Methods
Cell culture
Hep3B, HepG2, Huh7, and HEK 293T cells were main-
tained in a Dulbecco’s modified Eagle’s medium (Gibco,
USA) supplemented with 10% fetal bovine serum (FBS)
(Hyclone, USA), 100 units/mL penicillin, and 0.1% (w/v)
streptomycin. For cells treated with cytokines, 10% FBS-
cultured medium was removed and washed twice with
PBS before adding 2% FBS-cultured medium with IL-1ʲ
(Peprotech, USA).
Plasmid construction and virus preparation
Flag epitope-tagged ESE-1 from the pCI-ESE-1 plasmid
[12] was subcloned into pCR3.1 plasmid with Hind III
and EcoR V to produce pCR3.1-ESE-1 plasmid. pCR3.1-
ʔ ESE-1 was generated by removing the ETS domain
(272 to 354 amino acids) of ESE-1 [12]. Meanwhile, de-
letion ESE-1 binding site mutant promoters were formed
by fusing polymerase chain reaction (PCR) based on the
PGL3-basic firefly luciferase reporter vector with GP73
promoter (−2618/−19) [32]. All PCR primers are shown
in Additional file 4: Table S1.
Plasmid pSuper-shESE-1, which was used to generate
siRNA against ESE-1, was constructed by inserting the
target sequence into pSuper (Oligoengine, USA) in site
with Bgl II and Hind III. The inserted sequences are spe-
cified in Additional file 4: Table S1. Infectious shESE-1
virus particles were then generated by co-transfecting
HEK293T cells with pSuper-shESE-1 and packaging
plasmid [33,34]. At 48 h after transfection, the super-
natant that contained the virus was filtered through 0.45
ʼm filters and was incubated with the target cells with 4
mg/mL polybrene (Sigma, USA).
Quantitative PCR
For mRNA quantification, total RNA from cells or liver
tissue was prepared with Trizol reagent according to the
manufacturer’s protocol (Sangon). cDNA was synthe-
sized using a reverse transcription kit (Takara). SYBR
real-time PCR was performed with specific primers
(Additional file 4: Table S1) in a CFX96 Real-Time PCR
Detection System (Bio-rad, USA), and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) or 18S was used as
an internal control for standardization. All reactions were
performed in triplicate.
Western blot analysis
Cells were resuspended in 100 ʼL of radio immunopre-
cipitation assay (RIPA) buffer (Beyotime) supplemented
with protease inhibitor cocktail (Roche). Cell lysate was
analyzed by using 12% SDS-PAGE and was transferred
onto polyvinylidene fluoride membranes. 5B12 [7] and
ab1392 (Abcam) antibodies were applied to detect GP73
and ESE-1 proteins, respectively. Protein level was nor-
malized by GAPDH, a housekeeping protein detected by
mouse anti-GAPDH monoclonal antibody (Kang Xiang,
Shanghai).
Transfection and reporter assays
Cells (2 × 10
4) were seeded in 96-well culture plates 12
h before transfection. The GP73 promoter and pCR3.1-
ESE-1 plasmid or ʔ ESE-1 or empty vectors together
with pRL-TK plasmids were cotransfected into the cells
with Lipo2000™ (Invitrogen). The cells were harvested
36 h after transfection and were analyzed by using the
Dual-glo luciferase assay kit (Promega). All transfections
were performed in triplicate and repeated at least thrice.
Firefly luciferase activity was normalized to renilla lucif-
erase activity for each sample.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were
performed by using ChIP assay kit (P2078, Beyotime)
following the manufacturers’ instructions. Hep3B cells
(1 × 10
7) were plated and transfected with Flag-tagged
ESE-1 expression vectors and were subsequently incu-
bated with or without 10 ng/mL IL-1ʲ f o r2h .A f t e r3 6
h, cross-linking was performed with 1% formaldehyde
for 10 min at room temperature. Nuclei membrane was
impaired, and chromatin was sheared by sonication for
7 min to 10 min, producing 250 bp to 1000 bp frag-
ments. Chromatin was then incubated overnight after
mixing with 50 ul of protein G/A magnetic beads (Life
Technology) and 4 ul of nonspecific mouse IgG (Chemicon)
or 4 ul of monoclonal mouse Flag antibody (F1804, Sigma)
for 6 h at 4°C with rotation. DNA was precipitated
using 10% Chelex-100, which was subjected to quanti-
tative PCR (qPCR) analysis. The primers used are listed
in Additional file 4: Table S1. Negative control was per-
formed by using the control primer of the kit.
Immunohistochemical and immunofluorescence analysis
The mouse liver inflammation model was constructed by
intraperitoneally injecting 35 ng/kg of LPS and 250 mg/kg
of D-galactosamine [19]. The protocol was approved by
the Institutional Animal Care and Use Committee of the
Guangzhou Institutes of Biomedicine and Health, Chinese
Academy of Sciences (IACUC ID: 2013016). Liver tissues
were collected at different time points and were subse-
quently fixed and sectioned (3 ʼm thick). By using
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5: Figure S4) and anti-mouse HRP-conjugated secondary
antibody, mouse GP73 was detected and subsequently
stained with 3,3′-fiaminobenzidine solution (ZSGB-BIO,
Beijing). The sections were visualized with motic digital
slices scanning and application system (Motic VM V1).
For immunofluorescence analysis, full-thickness human
liver tissue samples were obtained from the Guangzhou
Overseas Chinese Hospital. The s et i s s u es a m p l e sw e r ef i x e d
and sectioned (3 ʼmt o4ʼm thick), and hematoxylin–
eosin (HE) staining was completed in successional sections.
Human GP73 was localized using antibody 5B12 and was
incubated with sheep anti-mouse immunoglobulin conju-
gated to fluorescein isothiocyanate (Chemicon, USA). ESE-
1 was labeled using ab1392 antibody (Abcam) and was
incubated with goat anti-rabbit antibody conjugated to
rhodamine (Chemicon, USA). Nuclei were counterstained
with 4,6-diamidino-2-phenylindole (DAPI; KPL, USA).
The sections were viewed with a confocal microscope
(LSM 710; Zeiss, Germany).
Statistical analysis
Data were reported as mean ± standard error of at least
three independent experiments, and statistical analysis
was performed by using ANOVA, followed by Student’s
t-test (*: p < 0.05; **: p < 0.01; ***: p < 0.001).
Additional files
Additional file 1: Figure S1. The correlation of ESE-1 and GP73
expression in other hepatocytes. Human hepatocytes: Bel-7402, QSG-7701,
HL-7702(L-02); Mouse hepatocytes: Hep1-6, AML-12.
Additional file 2: Figure S2. The location of ESE-1 protein in Hep3B
and Huh7 cells with or without IL-1β stimulation.
Additional file 3: Figure S3. The time course expression of ESE-1 and
GP73 mRNA in Hep3B cells with IL-1β stimulation.
Additional file 4: Table S1. Sequences of PCR primers used in this study.
Additional file 5: Figure S4. Validation of mouse GP73 (10B4) antibody.
(A) Flag epitope-tagged pCR3.1-mGP73 plasmids were transfected into
293T cells; mouse GP73 (mGP73) expression was detected using anti-flag
antibody (F1804, Sigma) or anti-mGP73 antibody (10B4) with Western
blot. (B) The location of mGP73 was tested using 10B4 antibody in Hep1-6
cells with immunocytochemistry. Black arrows signified the location of
mouse GP73 protein.
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